Spanish biotech Sanifit has begun a Phase III trial with what could be the first therapy for calciphylaxis, a rare disease which leads to the death of around 55% of patients within the first year of diagnosis.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?